DUSA Pharmaceuticals, Inc. was founded in 1991 and is based in Wilmington, Massachusetts. DUSA Pharmaceuticals, Inc., an integrated dermatology pharmaceutical company, develops and markets Levulan photodynamic therapy (PDT) and other products for common skin conditions in the United States and internationally. Its products include Levulan Kerastick 20% Topical Solution with PDT and the BLU-U brand light source for the treatment of non-hyperkeratotic actinic keratoses of the face or scalp. The BLU-U is used without Levulan to treat moderate inflammatory acne vulgaris and general dermatological conditions. The company is also developing non-PDT drug products, including Nicomide, Nicomide-T, AVAR products, ClindaReach, Meted, and Psoriacap products.

Light Sciences Oncology, Inc. company is in the business of developing its proprietary Light Infusion Therapy (Litx). Litx is a novel treatment for solid tumors, in which a flexible light-emitting diode (LED) is inserted into a tumor, followed by an injection of Aptocine (talaporfin sodium), a light-activated drug. Once the LED activates Aptocine, molecular oxygen is converted into singlet oxygen, killing tissue within the LED's scope and shutting down the blood supply to the area. The treatment is designed for use on cancers including liver and prostate cancers and glioma (brain tumors).

Lundbeck Inc. (formerly Ovation Pharmaceuticals) hopes to earn its applause by staying on the look-out for niche pharmaceuticals that larger drugmakers cast aside. The company's focus is on developing drugs for central nervous system (CNS) disorders, as well as cancer drugs and hospital-based therapies. Its FDA-approved products for neurological conditions include treatments for ADHD, anxiety, and seizures; the company has several CNS products in its development pipeline, such as epilepsy drugs, drug addiction therapies, and seizure medications. Among its other marketed products are several oncology drugs, as well as a treatment for lead poisoning. The company was acquired by Denmark-based H. Lundbeck in 2009.

Genome Explorations Inc. was founded by Dr. Divyen H. Patel to provide academic and industrial institutes with a 'Complete Solution' for Genotyping, Gene expression and miRNA profiling. Dr. Patel initiated and ran the Affymetrix GeneChip processing core at St. Jude Children's Research Hospital. The finding's from one of the many studies conducted through his core was described in a seminal study on the cover of Cancer Cell (Cancer Cell Vol. 1 133-143 March 2002). The study showed for the first time that microarray technology could be used to enhance diagnosis of pediatric leukemia and could also be used to evaluate prognostic outcome. The extensive experience gained through working with scores of investigators on many varying projects has made Genome Explorations Inc. the number one choice for Investigators worldwide.

Newron Pharmaceuticals focuses its brainpower on finding remedies for nervous system disorders. As a biopharmaceutical company focused on developing treatments for central nervous system diseases, Newron is developing a pipeline that includes treatments for Parkinson's disease and neuropathic back pain (pain which results from damage to nerve cells). The company is also in the early stages of developing treatments for Restless Leg Syndrome and Alzheimer's disease, as well as other neuropathic pain disorders. Newron is currently partnered with Merck Serono for development of Newron's primary drug product Safinamide, a Parkinson's treatment.

Neurocrine Biosciences, Inc. was founded in 1992 and is based in San Diego, California. Neurocrine Biosciences, Inc. engages in the discovery and development of drugs for the treatment of neurological and endocrine-related diseases and disorders in the United States. The company develops drugs for endometriosis, anxiety, depression, pain, diabetes, irritable bowel syndrome, insomnia, and other neurological and endocrine related diseases and disorders. Its products in clinical development comprise Elagolix, a Phase II product for Endometriosis; CRF1 Antagonist, a phase II product for mood disorders; CRF2 Peptide Agonist, a phase II drug for Cardiovascular related diseases; CRF1 Antagonist, a Phase I product for treating Mood Disorders and Irritable Bowel Syndrome; and Elagolix, a Phase I product for treating Benign Prostatic Hyperplasia and Uterine Fibroids. The company's research programs include Vesicular Monoamine Transporter 2 Inhibitor for movement disorders and schizophrenia; Glucose Dependent Insulin Secretagogues for type II diabetes; Antiepileptic drugs for epilepsy and bipolar disorder; and GnRH Antagonists for hormone dependent diseases and oncology. It has strategic alliances with GlaxoSmithKline to develop and commercialize CRF antagonists for psychiatric, neurological, and gastrointestinal diseases; and Dainippon Sumitomo Pharma Co. Ltd. to develop and commercialize indiplon in Japan.

Bayhill Therapeutics knows that some immune responses are just way out of line. The biopharmaceutical developer is designing vaccines to eliminate problematic immune responses and restore the immune system to its normal state, known as "tolerance." Its product candidate BHT-3009 is being studied in clinical trials as a treatment for multiple sclerosis while its other leading candidate BHT-3021 is in clinical trials for the treatment of type 1 diabetes. The company's pre-clinical candidate, BHT-3034 is being developed as a treatment for myasthenia gravis, an autoimmune disease that causes interruption in the transmission of nerve impulses to muscles.

SCOLR Pharma, Inc. is a specialty pharmaceutical company, which through its Controlled Delivery Technology (CDT) platforms, develops prescription, over-the-counter (OTC) and nutritional products. The Company has developed multiple private-label controlled release nutritional products incorporating its CDT platforms that are sold by national retailers. The Company’s lead product candidate is a CDT-based controlled release formulation of ibuprofen, an analgesic used for the treatment of pain, fever and inflammation. It completed the pivotal phase III trial to evaluate the safety and efficacy of its 12 hour CDT 600 milligram controlled release ibuprofen for the OTC market. In addition, the Company submitted its first abbreviated new drug application (ANDA) for its 12-hour pseudoephedrine product on August 5, 2008.

Amylin Pharmaceuticals was founded in 1987 and is based in San Diego, California. Amylin Pharmaceuticals, Inc. is a biopharmaceutical company engaged in the discovery, development and commercialization of drug candidates for the treatment of diabetes, obesity and other diseases. As of December 31, 2008, the Company was marketing two medicines to treat diabetes: BYETTA (exenatide) injection and SYMLIN (pramlintide acetate) injection. In addition to its marketed products, the Company is working with Eli Lilly and Company (Lilly) and Alkermes, Inc. (Alkermes) to develop exenatide once weekly. The Company maintains a discovery research program focused on peptide and protein therapeutics.

Omrix Biopharmaceuticals helps keep blood in its place in the operating room. The company develops biosealants derived from human plasma to control bleeding during surgical procedures. The biosealants contain naturally occurring proteins that clot and adhere to tissue. Johnson & Johnson's Ethicon subsidiary markets and distributes these products under the names Evicel in the US and Quixil in Europe. Omrix's Evithrom thrombin product was developed with Ethicon primarily for neurosurgery. The FDA has approved both for hemostasis (minimizing blood loss) during surgery. Omrix was acquired by Johnson & Johnson in 2008 and became part of the Ethicon division.

Inviting Real Estate Agents, Job Placements Agents, Educational Institutes, Software Service Providers, Real Estate Builders, Marriage Bureaus, Travel Agents, Restaurant Owners, Health & Fitness Centers and other Local Businesses to Post a FREE Classified Advertisement on Cootera.com Classifieds Website.